Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Leukemia 7Myelodysplastic Syndromes 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Myeloid, Acute 3Anemia, Refractory 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1

Interventions

Cyclophosphamide 9fludarabine phosphate 7Cyclosporine 7Peripheral Blood Stem Cell Transplantation 6Mycophenolic Acid 6Busulfan 6Tacrolimus 5Radiotherapy 5Methotrexate 5Antilymphocyte Serum 5Filgrastim 4Cord Blood Stem Cell Transplantation 4Sirolimus 3Methylprednisolone 3Melphalan 3Rituximab 2Moxifloxacin 2Flow Cytometry 2Etoposide 2Cytarabine 2Arsenic Trioxide 2Alemtuzumab 2venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic-Myeloproliferative Diseases × Arsenic Trioxide × Clear all
NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

CTI BioPharma

Phase 2 Terminated
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00104806 2018-08-10

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Wake Forest University Health Sciences

Phase 2 Terminated
5 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡